PDL BioPharma Inc

PDL BioPharma — Q3 2017 Earnings Presentation

15 slides from PDL BioPharma's earnings presentation, Nov 2, 2017

  1. Slide 1: Third Quarter 2017 Financial Results Conference Call

    PDL Third Quarter 2017 Financial Results Conference Call November 2, 2017

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua

  3. Slide 3: Building Value Through Investments

    Building Value Through Investments o Focused on growth in order to continue value creation for shareholders. o Strong financial position enables us to continue to seek high quality acquisition candidates. Pleased with caliber of investment opportunities. » Finished third quarter with over $500 milli

  4. Slide 4: Noden Background

    Noden Background o Noden Pharma = Platform upon which to build a specialty pharmaceutical company. = PDL now owns 100% of Noden companies. = Noden already has two products on the market—both indicated for hypertension. —Tekturna and Tekturna HCT, as they are known in the US, and Rasilez® and Rasilez

  5. Slide 5: Building Profitable Growth in US

    Building Profitable Growth in US o Reported revenues on the Noden products for Q317 of $15.1 million. o In the process of turning the trajectory toward profitable growth. o Noden products have not been adequately marketed for several years. o Very capable sales team of 65 people now in place. o Refi

  6. Slide 6: Messages from the Sales Team

    Messages from the Sales Team o Hypertension is a generic market with a large unmet need but very little promotional activity. It is exactly the kind of market where a relatively small commercial team, promoting a product that addresses a significant part of that unmet need, can have an impact. o Alm

  7. Slide 7: Maximizing Profitability— Ex US

    Maximizing Profitability— Ex US o On track in transferring marketing authorizations for Rasilez to our country distributors and starting to book sales. = Expect the transfers to be complete in most markets by year end, with some Asian markets being completed in early 2018. o Assessing each country o

  8. Slide 8: Dominique Monnet, President

    Dominique Monnet, President o PDL appointed Dominique Monnet to position of president. o Brought over 30 years international biotech/pharma business experience. o Will work closely with Noden’s leadership and on future PDL acquisitions. o Believe his proven track record of achieving commercial succe

  9. Slide 9: Neos Therapeutics

    PDL Neos Therapeutics

  10. Slide 10: Royalty & Debt Investments

    16 Royalty & Debt Investments Royalty Transaction, ‘Senior Secured Financing Wellstat Diagnostics, LUC we $44,000,000 November2012 Royalty Acquisition 3% Depomed 240,500,000 October 2013, Financing A | LENSAR $60,000,000 October 2013, ‘Senior Secured inaneing Oo DURATA $70,000,000 October 2013, Roya

  11. Slide 11: PDL Sells kaleo Asset

    "1 PDL Sells kaleo Asset o Entered into agreement on September 21, 2017 with third party purchaser. o Sold entire interest in kaleo note. o The purchaser paid PDL an amount equal to 100% plus a premium of approximately 1% for the aggregate purchase price of $141.7 million. « This is subject to an 18

  12. Slide 12: Settlement with Valeant

    Settlement with Valeant o On October 27", we and Depomed entered into a settlement agreement with Valeant Pharmaceuticals International, Inc. o Agreement resolves all matters addressed in Depomed lawsuit of September 7, 2017 relating to underpayment of royalties by Valeant. o Litigation is dismissed

  13. Slide 13: Third Quarter 2017 Financials

    Third Quarter 2017 Financials Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except per share amounts) (unaudited) 2017 2016 2017 2016 Royaties from Queen et al. patents $1443 _§ 14.958 _S 31,884 _§ 150,645 Royalty rights - change in fair value 35,353 16.085 132.224

  14. Slide 14: Third Quarter 2017 Financials

    Third Quarter 2017 Financials Condensed consolidated balance sheet (unaudited) September 30, December 31, 2017 2016 Cash, cash equivalents and investments $ 516,494 $ 242,141 Total notes receivable $ 70,636 $ 270,950 Total royalty rights - at fair value $ 351,969 $ 402,318 Total assets $ 1,223,838 $

  15. Slide 15: Question and Answer Session

    PDL Question and Answer Session

PDL BioPharma — Q3 2017 Earnings Presentation on 6ix